Genmab A GMAB
NASDAQ GMAB
$54.07 -1.74 (-3.12%)
At close: Nov 10, 2026 · 4:00 PM EST

Genmab A (GMAB) EBT Margin (2023 - 2026)

Updated

Genmab A (GMAB) reported EBT Margin of 25.54% for the quarter ended Jun 30, 2026, up 17.28 percentage points from the prior quarter.

Analysis

Genmab A (GMAB) EBT Margin (2023 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Genmab A's EBT Margin came in at 31.87%; for the year ended Dec 31, 2025, it came in at 32.37%, down 10.12 percentage points from the prior year.

  • By year, EBT Margin came in at 42.49% in the year ended Dec 31, 2024 (+8.30 pp) and 34.18% in the year ended Dec 31, 2023.
  • Five-year quarterly EBT Margin spans a low of 8.26% in the quarter ended Mar 31, 2026 and a high of 56.66% in the quarter ended Sep 30, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 0.13%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 27.75%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 26.27%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 45.21%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 36.90%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 20.41%
10 Genmab A 3.47 Bn -3.13 Bn 1.10 Bn 29.82%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 29.82%
Jun 30, 2026 25.54%
Mar 31, 2026 8.26%
Sep 30, 2025 47.16%
Jun 30, 2025 45.73%
Mar 31, 2025 34.13%
Sep 30, 2024 31.00%
Jun 30, 2024 39.41%
Mar 31, 2024 41.29%
Sep 30, 2023 56.66%
API Access

Genmab A EBT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebt-margin&ticker=GMAB&period=max&api_key=YOUR_API_KEY